Inequalities in oncology care: Economic consequences of high cost drugs

M.G.H. Niezen, Elly A Stolk, Adri Steenhoek, Carin A Uyl-De Groot

Research output: Contribution to journalArticleScientificpeer-review

20 Citations (Scopus)


The expenditures for hospital drugs are continuously increasing, and grow much faster than the global hospital budgets do. This explosive growth is caused mainly by a few so-called 'expensive drugs' of which the oncolytics form the main part. The global budgets should stimulate more effective provision of care ('technical efficiency'), however the room for technical efficiency is decreasing. Hospitals thus have to make impossible choices, so that eventually equal access can no longer be guaranteed. If no other policies are applied, health care goals will no longer be met. This paper tries to map the contours of the current problem and its possible solutions. It is time governments take up their responsibility and take back control.

Original languageEnglish
Pages (from-to)2887-92
Number of pages6
JournalEuropean Journal of Cancer: Official journal for European Organization for Research and Treatment of Cancer (EORTC)
Issue number17
Publication statusPublished - Nov 2006
Externally publishedYes


  • Antineoplastic Agents
  • Budgets
  • Costs and Cost Analysis
  • Forecasting
  • Health Expenditures
  • Health Policy
  • Hospital Costs
  • Humans
  • Neoplasms
  • Socioeconomic Factors


Dive into the research topics of 'Inequalities in oncology care: Economic consequences of high cost drugs'. Together they form a unique fingerprint.

Cite this